MiNK Therapeutics, Inc. — 2021 Form 10-K
Business context and reporting period. This is an annual report for the fiscal year ended December 31, 2021, not a standalone fourth-quarter report. MiNK is a clinical-stage biotechnology company developing allogeneic, off-the-shelf invariant natural killer T (iNKT) cell therapies. Its lead candidate, AGENT-797, was in Phase 1 trials; engineered iNKT candidates remained preclinical. The company completed its IPO in October 2021 and continued to be majority-owned by Agenus.
Financial performance and position
| Metric | 2021 | 2020 |
|---|---|---|
| Product or royalty revenue | None reported | None reported |
| Research and development expense | $14.0 million | $9.5 million |
| General and administrative expense | $4.6 million | $1.3 million |
| Operating loss | $28.4 million | $14.6 million |
| Net loss | $30.2 million | $16.2 million |
| Net loss per share, basic and diluted | $1.16 | $0.67 |
| Net cash used in operating activities | $12.8 million | $8.3 million |
At December 31, 2021, cash was $38.9 million, versus $2.7 million a year earlier. Total assets were $40.2 million and current liabilities were $16.5 million. The balance sheet showed no convertible affiliated note at year-end; the Agenus note converted into 5,451,958 common shares at the IPO. Accumulated deficit was $82.9 million. The filing reports no product revenue, so commercial margins are not applicable; it does not provide a clear operating-margin measure.
Material changes versus 2020
- Net loss increased by $14.0 million; R&D expense rose 47%, primarily with increased preclinical work, clinical trial activity, Agenus service allocations and activity in the UK subsidiary.
- G&A expense increased 260%, reflecting higher professional fees, stock-based compensation and Agenus service allocations.
- Cash increased following the IPO. The financial statements report approximately $39.8 million of IPO net proceeds; the Item 5 discussion instead states approximately $42.8 million. This inconsistency should be reconciled.
- The Agenus convertible note, with $45.5 million principal plus accrued interest, converted to equity in October 2021. The filing also records a $9.8 million 2021 expense from the change in the note’s fair value.
- The company recognized a $356,000 gain from forgiveness of a Paycheck Protection Program loan.
Outlook, commentary and risks
- Management stated that year-end cash was expected to fund operating and capital needs for more than one year from issuance of the financial statements. The company anticipated continued operating losses and negative operating cash flows and said it may need additional capital through partnerships, debt or equity financing.
- Management expected 2022 updates from AGENT-797 trials, including multiple myeloma data in the fourth quarter, solid-tumor preliminary readouts, and GvHD top-line data in the second half. It also expected to pursue IND filings for two preclinical engineered programs. These are expectations, not guaranteed milestones.
- The company reported an early ARDS trial survival benefit exceeding 75% and no related cytokine release syndrome or neurotoxicity at doses up to one billion cells. These findings are preliminary; the filing cautions that interim results may change and are not necessarily predictive of later results.
- A $5.3 million Walloon Region repayable advance is included in current liabilities. Repayment was uncertain: the government expected reimbursement, while MiNK stated it did not plan to exploit the research results.
- Key risks include clinical and regulatory failure, manufacturing scale-up and supply, competition, need for further capital, reliance on Agenus for services and facilities, and Agenus’s approximately 78.7% ownership. The filing also notes that COVID-19 reduced ARDS trial enrollment as hospitalizations declined.
- The independent auditor gave an unqualified opinion on the financial statements. Management reported effective disclosure controls and internal control over financial reporting; auditor attestation was not required.
Most important facts for investors to verify
- Reconcile the IPO net-proceeds figures: approximately $42.8 million in Item 5 versus approximately $39.8 million in MD&A and the financial statements.
- Track cash burn, financing needs and the stated runway against actual operating and clinical spending.
- Confirm the status and amount of any repayment due on the $5.3 million Walloon Region advance.
- Assess subsequent AGENT-797 trial data, patient numbers, durability, safety and whether preliminary ARDS results are confirmed.
- Monitor delivery of planned 2022 clinical and IND milestones, and MiNK’s continuing dependence on Agenus-controlled services and facilities.